Two dose levels of maintenance treatment with extended-release buprenorphine (Sublocade) improved opioid abstinence in patients with high-risk opioid use disorder (OUD), a randomized trial showed.
A seven-day, extended-release version of buprenorphine — a treatment for opioid use disorder (OUD) that can reduce opioid use and overdose deaths — is safe and effective for people with OUD ...
Both monthly maintenance doses (100 mg and 300 mg) improved opioid abstinence and were well-tolerated with no new safety signals identified. Post-hoc analyses indicated the 300-mg monthly maintenance ...
LUND, Sweden, June 25, 2024 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3 ...
Please provide your email address to receive an email when new articles are posted on . Buprenorphine, especially the extended-release formulation, reduced future ED visits in patients with opioid use ...
For adults with high-risk opioid use disorder (OUD), both 100-mg or 300-mg monthly maintenance injections of extended-release buprenorphine improved opioid abstinence, but the higher dose seemed to ...
Los Angeles County is struggling to keep up with a rising demand for opioid addiction medications within its jails, forcing it to place more than 800 inmates on waitlists for treatment in October and ...
In a randomized trial, both 100-mg and 300-mg monthly maintenance doses of extended-release buprenorphine improved opioid abstinence in patients with high-risk opioid use, with no new safety signals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback